Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer

NCT06614660 | Active Not Recruiting DMC

• 1 other identifier: 204-160-01
• Study Type: observational
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, the investigators constructed an imaging-metabolism prediction model for colorectal cancer by analysing the imaging and metabolomics features of colorectal cancer, in order to further adjust and guide the treatment plan.

Conditions

Colorectal Cancer; Imaging; Metabolomics; Prognosis; Genomics

Keywords

colorectai cacner; imaging genomics; metabolomics genomics; prognosis

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Overall survival was defined as time from date of diagnosis until the date of death from any cause or or loss to follow-up.

  From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months.

Study Arms (1)

the colorectal cancer group

Metabolism genomics and imaging genomics were collected via blood and CT images for colorectal cancer patients.

Other: Metabolism genomics and imaging genomics

Interventions

Metabolism genomics and imaging genomics OTHER

Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\'s blood specimen was collected to collect metabolism genomics and imaging genomics.

the colorectal cancer group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed with colorectal cancer and undergoing radical surgery for colorectal cancer at this clinic center were invited.

You may qualify if:

• met the diagnostic criteria for gastrointestinal tumours;
• age \>18 years;
• planned to undergo surgery for gastrointestinal tumours according to the guidelines;
• signed an informed consent form; and e) agreed to undergo a biopsy in order to collect tissue from the tumour lesion.

You may not qualify if:

• contraindications to imaging;
• withdrawal from the study cohort midway;
• metastatic foci in the liver, lung or other distant organs confirmed by CT, MRI or ultrasound imaging;
• gastrointestinal tumours combined with haemorrhage, obstruction or perforation;
• women who were pregnant, breastfeeding or planning to become pregnant during the study period.

Sponsors & Collaborators

• First Affiliated Hospital of Chongqing Medical University: lead

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

Location

Related Publications (3)

• Zhang G, Zhang Z, Pei Y, Hu W, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics. Front Endocrinol (Lausanne). 2023 Oct 20;14:1272806. doi: 10.3389/fendo.2023.1272806. eCollection 2023.

  PMID: 38027108 BACKGROUND

• Cicalini I, Chiarelli AM, Chiacchiaretta P, Perpetuini D, Rosa C, Mastrodicasa D, d'Annibale M, Trebeschi S, Serafini FL, Cocco G, Narciso M, Corvino A, Cinalli S, Genovesi D, Lanuti P, Valentinuzzi S, Pieragostino D, Brocco D, Beets-Tan RGH, Tinari N, Sensi SL, Stuppia L, Del Boccio P, Caulo M, Delli Pizzi A. Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study. Radiol Med. 2024 May;129(5):712-726. doi: 10.1007/s11547-024-01811-0. Epub 2024 Mar 27.

  PMID: 38538828 BACKGROUND

• Pan Y, Lei X, Zhang Y. Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach. Med Res Rev. 2022 Jan;42(1):441-461. doi: 10.1002/med.21847. Epub 2021 Aug 4.

  PMID: 34346083 BACKGROUND

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: September 24, 2024
• First Posted: September 26, 2024
• Study Start: September 1, 2024
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: September 27, 2024

Record last verified: 2024-09

Locations

CN (1)